trial
as of 2026-07-01CLOZAPINE Response in Biotype-1
NCTId NCT04580134
at a glance
Phase 4 · Recruiting
Enrollment 524 (estimated)
Sponsored by University of Texas Southwestern Medical Center
Primary completion 2027-04-30
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 4
Status
Recruiting
Enrollment
524 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2022-03-01
Primary completion
2027-04-30
Eligibility
ALL · 18 Years · 60 Years
Interventions & indications
Sponsors
University of Texas Southwestern Medical CenterLead Sponsor
National Institute of Mental Health (NIMH)Collaborator
Beth Israel Deaconess Medical CenterCollaborator
Hartford HospitalCollaborator
University of GeorgiaCollaborator
University of ChicagoCollaborator
Investigators
1
Carol A. Tamminga, M.D.Principal Investigator
Sites
5 total
Hartford, United StatesAthens, United StatesChicago, United StatesBoston, United StatesDallas, United States
Facts & assertions
4 sourced
Enrollment
524
Phase
PHASE4
Primary Completion Date
2027-04-30
Status
RECRUITING
relationships
The graph out of here
drug
drug
drug
lead_sponsor
collaborator
indication
investigator
person